PRT064445 clinical trials

Studies by the year they started

14 studies that test it; most in 2012 (5)

Who runs them

Industry 14 · Other 0

Portola Pharmaceuticals (9) · Alexion Pharmaceuticals, Inc. (3) · AstraZeneca (2)

Often tested with

Tested in the same studies.

Rivaroxaban (3) · Apixaban (3) · Enoxaparin (2) · Edoxaban (1)

Studies

Open first, then newest update. How each study uses PRT064445 is read from its arms, and is right about nine times in ten.

Testing it · 14

• A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT07312851Written as Andexanet alfa
• A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or ProcedureWithdrawnPhase 3AstraZenecaNCT05926349Written as Andexanet alfa
• Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa InhibitorCompletedPhase 4Alexion Pharmaceuticals, Inc.NCT03661528Written as andexanet alfa
• A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet AlfaCompletedPhase 1Portola PharmaceuticalsNCT03083704Written as Andexanet alfa (Gen 1 Process 2)
• A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of ApixabanCompletedPhase 3Portola PharmaceuticalsNCT02207725Written as Andexanet
• A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban DosingTerminatedPhase 2Portola PharmaceuticalsNCT03330457Written as Andexanet alfa (bolus)
• Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 1 of 4)CompletedPhase 2Portola PharmaceuticalsNCT01758432Written as PRT064445/Apixaban
• Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor AntidoteCompletedPhase 1Portola PharmaceuticalsNCT03218241Written as PRT064445
• Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent SurgeryTerminatedPhase 2Alexion Pharmaceuticals, Inc.NCT04233073Written as andexanet alfa
• Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)CompletedPhase 2Portola PharmaceuticalsNCT03551730Written as PRT064445/Enoxaparin
• Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 2 of 4)CompletedPhase 2Portola PharmaceuticalsNCT03578146Written as PRT064445/Rivaroxaban
• Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)CompletedPhase 2Portola PharmaceuticalsNCT03551743Written as PRT064445/Edoxaban
• A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of RivaroxabanCompletedPhase 3Portola PharmaceuticalsNCT02220725Written as Andexanet
• A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)CompletedPhase 3Alexion Pharmaceuticals, Inc.NCT02329327Written as Andexanet

Codes

What other systems call PRT064445 · ClinicalTrials.gg INT006271

• RxNorm 2045114One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.